has received speaker and/or advisory fees from Novo Nordisk, Eli Lilly, AstraZeneca, Janssen, Pfizer and Merck Sharp & Dohme and a research grant from Novo Nordisk
How long can I take GLP-1 therapy
In addition, the rise of direct-to-consumer channels, digital health platforms, and personalized nutrition plans is making these products more accessible
Alternative multi-agonists for obesity treatment GLP-1R/GcgR dual agonists have shown impressive metabolic benefits and inspired the search for what now represents a growing class of rationally designed multi-agonists with differentiated mechanisms of action for obesity therapy
Athletes should not use Ipamorelin if subject to drug testing
Because this was apparent following acute and steady-state administration, differences in plasma half-lives alone do not explain this difference